MOUNTAIN VIEW, Calif., Feb. 5 MAPPharmaceuticals, Inc. (Nasdaq: MAPP), an emerging pharmaceutical company,announced today that Stephen B. Shrewsbury, M.B., Ch.B., Chief MedicalOfficer, will be leaving the company for personal reasons in early March 2008.Dr. Shrewsbury plans to provide consulting services to the company for aperiod of time after his departure.
"We want to thank Steve for his many contributions and wish him the bestin his future endeavors," said Timothy S. Nelson, President and ChiefExecutive Officer. "Steve has put into place a strong leadership team in theclinical organization to advance our two lead programs for pediatric asthmaand migraine through late-stage development."
"I am happy to have played a role in the development of our two leadproduct candidates, Unit Dose Budesonide (UDB) and MAP0004," stated Stephen B.Shrewsbury, M.B., Ch.B., Chief Medical Officer. "I made the difficult decisionto leave MAP Pharmaceuticals for personal reasons and believe that the companyis well positioned to move forward with these very promising programs."
About MAP Pharmaceuticals
MAP Pharmaceuticals develops and plans to commercialize new therapies forchildren and adults who suffer from diseases that the company believes are nottreated adequately by currently available medicines. The company usesproprietary inhalation technologies to enhance the therapeutic benefits andcommercial attractiveness of proven drugs, while minimizing risk bycapitalizing on their known safety, efficacy and commercialization history.The company has several product candidates in clinical development thataddress large market opportunities, including its two most advanced productcandidates: UDB, a proprietary version of nebulized budesonide for thepotential treatment of children with asthma; and MAP0004, a proprietaryversion of orally inhaled dihydroergotamine delivered by MAP Pharmaceuticals'Tempo(TM) inhaler for the potential treatment of migraine. The company is alsodeveloping a proprietary combination of an inhaled corticosteroid with along-acting beta2-agonist for the potential treatment of asthma and chronicobstructive pulmonary disease.
SOURCE MAP Pharmaceuticals, Inc.